A5079882176- Multiple and Secondary Primary Cancers
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Inflammatory Biomarkers in Disease Prognosis
Princess Margaret Cancer Centre
2024-2025
University Health Network
2024-2025
University of Toronto
2024
Mater Misericordiae University Hospital
2019
699 Background: Gemcitabine + cisplatin (GC) is a highly effective treatment for la/mUC. For patients who are ineligible standard GC, split-dose GC promising alternative. This study aimed to provide insights into the use of and factors influencing choice across 10 countries. Methods: Between January March 2024, an international cross-sectional was conducted via online survey physicians treating with la/mUC in Australia, Brazil, Canada, France, Germany, India, Italy, Spain, UK, US....
589 Background: Gemcitabine + cisplatin (GC) is one of the most effective and commonly used regimens in la/mUC. In GC, dosed at 70 mg/m 2 on day 1 a 3-week cycle; however, for many pts, impaired renal or cardiac function, neuropathy, poor performance status can preclude use cisplatin. A promising alternative split-dose where dose divided over days. We conducted an SLR NMA to better understand outcomes, toxicity, comparative effectiveness GC vs GCarboplatin (GCa), methotrexate vinblastine...
179 Background: Radium-223 ( 223 Ra) is a radiopharmaceutical that emits alpha particles and specifically targets bone metastases in mCRPC, where it has been shown to improve overall survival (OS). Since Ra induces double-strand DNA breaks, we hypothesized patients with HRD may exhibit heightened sensitivity Ra, resulting improved outcomes compared without HRD. Methods: This retrospective analysis was performed men mCRPC metastases, HRD, treated at PMCC. Demographics disease characteristics...
2023 Background: Brain metastases (BM) in advanced thyroid cancer are rare; however, they may be underreported as staging brain imaging is not routine. Prognostic features and molecular alterations for this group poorly described. We characterized the clinical of with BM evaluated differences survival. Methods: In single-center retrospective analysis, patients metastatic radioactive iodine refractory well-differentiated, poorly-differentiated, or medullary carcinoma seen at Princess Margaret...
9573 Background: Cancer related inflammatory processes have been shown to an important role in tumourigenesis, disease progression, and patient prognosis. An elevated neutrophil lymphocyte ratio (NLR) is associated with a worse outcome several malignancies. The relationship between NLR immune checkpoint blockade poorly understood. We sought investigate the of patients receiving inhibitors for metastatic melanoma (MM). aimed do this by comparing outcomes MM high ( > 3) low < NLRs...